HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab

Francesco Sclafani, Amitesh Roy, David Cunningham, Andrew Wotherspoon, Clare Peckitt, David Gonzalez de Castro, J Tabernero, Bengt Glimelius, Andres Cervantes, Zak Eltahir, Jacqueline Oates, Ian Chau

    Research output: Contribution to journalArticlepeer-review

    21 Citations (Scopus)

    Fingerprint Dive into the research topics of 'HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab'. Together they form a unique fingerprint.

    Medicine & Life Sciences